NICE-话题@MedSci

#NICE#

226篇内容 | 5108人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1289100, encodeId=9696128910000, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE将新型抗生素Fetcroja（cefiderocol）纳入试点报销范围, objectType=article, longId=205044, objectId=c2e52050447d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2e52050447d, replyNumber=0, likeNumber=0, createdTime=2021-01-01, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2e52050447d, moduleTitle=NICE将新型抗生素Fetcroja（cefiderocol）纳入试点报销范围, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2e52050447d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289099, encodeId=cdb8128909966, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE支持Calquence（acalabrutinib）治疗慢性淋巴细胞白血病, objectType=article, longId=204332, objectId=25ac2043325e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ac2043325e, replyNumber=0, likeNumber=92, createdTime=2020-12-10, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ac2043325e, moduleTitle=NICE支持Calquence（acalabrutinib）治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25ac2043325e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289098, encodeId=19cb1289098be, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE支持Braftovi治疗BRAF阳性转移性结直肠癌, objectType=article, longId=203872, objectId=e95e2038e2f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e95e2038e2f3, replyNumber=0, likeNumber=88, createdTime=2020-12-01, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e95e2038e2f3, moduleTitle=NICE支持Braftovi治疗BRAF阳性转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e95e2038e2f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289096, encodeId=13941289096f5, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE指南支持isatuximab治疗多发性骨髓瘤（MM）, objectType=article, longId=203866, objectId=3f4520386600, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f4520386600, replyNumber=0, likeNumber=91, createdTime=2020-12-01, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f4520386600, moduleTitle=NICE指南支持isatuximab治疗多发性骨髓瘤（MM）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f4520386600)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289097, encodeId=1eae128909e89, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE拒绝了诺华的Adakveo（crizanlizumab）, objectType=article, longId=203864, objectId=69b5203864d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69b5203864d9, replyNumber=0, likeNumber=60, createdTime=2020-12-01, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69b5203864d9, moduleTitle=NICE拒绝了诺华的Adakveo（crizanlizumab）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69b5203864d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289095, encodeId=6e5d128909553, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, objectType=article, longId=203477, objectId=04852034e7dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04852034e7dd, replyNumber=0, likeNumber=88, createdTime=2020-11-18, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04852034e7dd, moduleTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04852034e7dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289094, encodeId=92e4128909463, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=Venclyxto（venetoclax）治疗慢性淋巴细胞性白血病：已获NICE支持, objectType=article, longId=203281, objectId=a9322032812e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9322032812e, replyNumber=0, likeNumber=91, createdTime=2020-11-13, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9322032812e, moduleTitle=Venclyxto（venetoclax）治疗慢性淋巴细胞性白血病：已获NICE支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9322032812e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289093, encodeId=94c712890936d, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE支持Rinvoq治疗严重的活动性类风湿关节炎, objectType=article, longId=203140, objectId=2361203140f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2361203140f1, replyNumber=0, likeNumber=116, createdTime=2020-11-10, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2361203140f1, moduleTitle=NICE支持Rinvoq治疗严重的活动性类风湿关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2361203140f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289092, encodeId=149e12890926e, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=拜耳的Nubeqa获得NICE支持，用于治疗前列腺癌, objectType=article, longId=202563, objectId=5a2620256367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a2620256367, replyNumber=0, likeNumber=68, createdTime=2020-10-29, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a2620256367, moduleTitle=拜耳的Nubeqa获得NICE支持，用于治疗前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a2620256367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289091, encodeId=d8dc12890918c, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE积极推荐将赛诺菲的CD38单抗Sarclisa，用于治疗复发/难治性多发性骨髓瘤, objectType=article, longId=202215, objectId=ec9a2022152a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec9a2022152a, replyNumber=0, likeNumber=75, createdTime=2020-10-18, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec9a2022152a, moduleTitle=英国NICE积极推荐将赛诺菲的CD38单抗Sarclisa，用于治疗复发/难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec9a2022152a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289090, encodeId=6d83128909010, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤, objectType=article, longId=199756, objectId=08d0199e56b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08d0199e56b3, replyNumber=0, likeNumber=109, createdTime=2020-08-22, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08d0199e56b3, moduleTitle=靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08d0199e56b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289089, encodeId=b76e128908982, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, objectType=article, longId=198551, objectId=2cb719855145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb719855145, replyNumber=0, likeNumber=92, createdTime=2020-08-03, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb719855145, moduleTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb719855145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289088, encodeId=3e85128908872, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=FLT3抑制剂gilteritinib，获得英国NICE推荐治疗急性髓性白血病, objectType=article, longId=197734, objectId=6f8519e73405, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f8519e73405, replyNumber=0, likeNumber=89, createdTime=2020-07-20, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f8519e73405, moduleTitle=FLT3抑制剂gilteritinib，获得英国NICE推荐治疗急性髓性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f8519e73405)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289087, encodeId=9986128908e59, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤, objectType=article, longId=196520, objectId=4e2c19652009, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2c19652009, replyNumber=0, likeNumber=78, createdTime=2020-06-27, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2c19652009, moduleTitle=又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2c19652009)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289086, encodeId=5856128908654, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎, objectType=article, longId=196065, objectId=c775196065fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c775196065fc, replyNumber=0, likeNumber=0, createdTime=2020-06-19, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c775196065fc, moduleTitle=英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c775196065fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289085, encodeId=e9b01289085db, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者, objectType=article, longId=195930, objectId=68ef19593022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68ef19593022, replyNumber=0, likeNumber=70, createdTime=2020-06-17, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68ef19593022, moduleTitle=NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68ef19593022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289084, encodeId=caa2128908469, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, objectType=article, longId=195499, objectId=9c0719549995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0719549995, replyNumber=0, likeNumber=89, createdTime=2020-06-10, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0719549995, moduleTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0719549995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289083, encodeId=f207128908384, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, objectType=article, longId=194614, objectId=d3b0194614fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3b0194614fc, replyNumber=0, likeNumber=96, createdTime=2020-05-24, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3b0194614fc, moduleTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3b0194614fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289082, encodeId=628912890826a, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE支持罗氏的ADC药物Kadcyla恩美曲妥珠单抗，治疗HER2阳性的早期乳腺癌, objectType=article, longId=194124, objectId=c8f2194124ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8f2194124ca, replyNumber=0, likeNumber=55, createdTime=2020-05-15, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8f2194124ca, moduleTitle=英国NICE支持罗氏的ADC药物Kadcyla恩美曲妥珠单抗，治疗HER2阳性的早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8f2194124ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289081, encodeId=3f1412890819f, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, objectType=article, longId=193135, objectId=1689193135a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1689193135a7, replyNumber=0, likeNumber=95, createdTime=2020-04-30, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1689193135a7, moduleTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1689193135a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NICE

2020-05-29

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE将新型抗生素Fetcroja（cefiderocol）纳入试点报销范围

2021-01-01

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE支持Calquence（acalabrutinib）治疗慢性淋巴细胞白血病

2020-12-10

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE支持Braftovi治疗BRAF阳性转移性结直肠癌

2020-12-01

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE指南支持isatuximab治疗多发性骨髓瘤（MM）

2020-12-01

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE拒绝了诺华的Adakveo（crizanlizumab）

2020-12-01

fusion (审核中...)

前往app查看评论内容

#NICE#

全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍

2020-11-18

fusion (审核中...)

前往app查看评论内容

#NICE#

Venclyxto（venetoclax）治疗慢性淋巴细胞性白血病：已获NICE支持

2020-11-13

hb2008ye (审核中...)

前往app查看评论内容

#NICE#

NICE支持Rinvoq治疗严重的活动性类风湿关节炎

2020-11-10

fusion (审核中...)

前往app查看评论内容

#NICE#

拜耳的Nubeqa获得NICE支持，用于治疗前列腺癌

2020-10-29

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE积极推荐将赛诺菲的CD38单抗Sarclisa，用于治疗复发/难治性多发性骨髓瘤

2020-10-18

fusion (审核中...)

前往app查看评论内容

#NICE#

靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤

2020-08-22

fusion (审核中...)

前往app查看评论内容

#NICE#

PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法

2020-08-03

fusion (审核中...)

前往app查看评论内容

#NICE#

FLT3抑制剂gilteritinib，获得英国NICE推荐治疗急性髓性白血病

2020-07-20

fusion (审核中...)

前往app查看评论内容

#NICE#

又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤

2020-06-27

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎

2020-06-19

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者

2020-06-17

fusion (审核中...)

前往app查看评论内容

#NICE#

提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌

2020-06-10

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌

2020-05-24

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE支持罗氏的ADC药物Kadcyla恩美曲妥珠单抗，治疗HER2阳性的早期乳腺癌

2020-05-15

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎

2020-04-30

科室
- - 订阅+
  - 更多科室
工具
服务